The stock of Autolus Therapeutics plc ADR (AUTL) has seen a 12.29% increase in the past week, with a 19.25% gain in the past month, and a 8.59% flourish in the past quarter. The volatility ratio for the week is 5.93%, and the volatility levels for the past 30 days are at 6.18% for AUTL. The simple moving average for the last 20 days is 18.11% for AUTL stock, with a simple moving average of -3.25% for the last 200 days.
Is It Worth Investing in Autolus Therapeutics plc ADR (NASDAQ: AUTL) Right Now?
The 36-month beta value for AUTL is also noteworthy at 2.04. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AUTL is 236.60M, and at present, short sellers hold a 4.27% of that float. The average trading volume of AUTL on October 17, 2024 was 766.70K shares.
AUTL) stock’s latest price update
The stock price of Autolus Therapeutics plc ADR (NASDAQ: AUTL) has surged by 2.33 when compared to previous closing price of 4.51, but the company has seen a 12.29% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-09-06 that Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen’s blincyto, but obe-cel’s safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights.
Analysts’ Opinion of AUTL
Many brokerage firms have already submitted their reports for AUTL stocks, with Deutsche Bank repeating the rating for AUTL by listing it as a “Buy.” The predicted price for AUTL in the upcoming period, according to Deutsche Bank is $10 based on the research report published on November 09, 2023 of the previous year 2023.
Wells Fargo, on the other hand, stated in their research note that they expect to see AUTL reach a price target of $8. The rating they have provided for AUTL stocks is “Overweight” according to the report published on March 27th, 2023.
Bryan Garnier gave a rating of “Buy” to AUTL, setting the target price at $5 in the report published on March 17th of the previous year.
AUTL Trading at 17.92% from the 50-Day Moving Average
After a stumble in the market that brought AUTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.05% of loss for the given period.
Volatility was left at 6.18%, however, over the last 30 days, the volatility rate increased by 5.93%, as shares surge +19.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.30% upper at present.
During the last 5 trading sessions, AUTL rose by +11.80%, which changed the moving average for the period of 200-days by -32.82% in comparison to the 20-day moving average, which settled at $3.91. In addition, Autolus Therapeutics plc ADR saw -28.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUTL starting from Martin Pule, who proposed sale 698,741 shares at the price of $4.23 back on Sep 16 ’24. After this action, Martin Pule now owns shares of Autolus Therapeutics plc ADR, valued at $2,955,674 using the latest closing price.
Stock Fundamentals for AUTL
Current profitability levels for the company are sitting at:
- -15.19 for the present operating margin
- 0.52 for the gross margin
The net margin for Autolus Therapeutics plc ADR stands at -19.07. The total capital return value is set at -0.23. Equity return is now at value -61.80, with -35.87 for asset returns.
Based on Autolus Therapeutics plc ADR (AUTL), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at -0.64. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is -2.89.
Currently, EBITDA for the company is -188.46 million with net debt to EBITDA at 2.37. When we switch over and look at the enterprise to sales, we see a ratio of 65.97. The receivables turnover for the company is 0.33for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.50.
Conclusion
In summary, Autolus Therapeutics plc ADR (AUTL) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
